Latest Breaking News On - Classical hodgkin lymphoma - Page 1 : vimarsana.com

'Promising' Treatments Identified for Older Adults with Hodgkin Lymphoma

Recent research has shown encouraging results for older patients with classical Hodgkin lymphoma treated with Adcetris plus chemotherapy or Opdivo.

Nivolumab Market Size, Share And Growth Analysis For 2024-2033

Pembrolizumab With COPDAC-28 Consolidation Increases PET Negativity in Classical Hodgkin Lymphoma

The addition of pembrolizumab to COPDAC-28 consolidation may augment responses to treatment in pediatric and young adult patients with high-risk classical Hodgkin lymphoma who experience a slow early response to frontline chemotherapy.

IBI322 Shows Early Antitumor Efficacy in PD-1/PD-L1–Resistant Classical Hodgkin Lymphoma

Single-agent IBI322 elicited responses with favorable safety in patients with classical Hodgkin lymphoma that had become resistant to anti–PD-1/PD-L1 therapy, according to data from a phase 1 trial.

Dr Svoboda on the Implications of Nivolumab Plus AVD in Classical Hodgkin Lymphoma

Jakub Svoboda, MD, discusses the implications of the phase 3 SWOG 1826 trial of nivolumab plus doxorubicin, vinblastine, and dacarbazine in patients with advanced classical Hodgkin lymphoma.

Brentuximab Vedotin Plus Nivolumab/Chemo Elicits 98% ORR in Early-Stage Classical Hodgkin Lymphoma

Frontline treatment with the combination of brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine led to an overall response rate of 98% and a complete response rate of 93% in patients with early-stage, classical Hodgkin lymphoma.

Nivolumab With AVD Confers PFS Benefit Vs Brentuximab Vedotin Plus AVD in Advanced-stage Hodgkin Lymphoma

Nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (AVD) resulted in prolonged progression-free survival (PFS) compared with brentuximab vedotin plus AVD in patients with advanced-stage classical Hodgkin lymphoma.

Tessa Therapeutics Announces Updated Safety, Efficacy and Biomarker Data from Phase 2 Trial of Autologous CD30.CAR-T Therapy (TT11) in Relapsed or Refractory Classical Hodgkin Lymphoma

Tessa Therapeutics Announces Updated Safety, Efficacy and Biomarker Data from Phase 2 Trial of Autologous CD30.CAR-T Therapy (TT11) in Relapsed or Refractory Classical Hodgkin Lymphoma GlobeNewswire December 12, 2022 Updated Results from CHARIOT Phase 2 trial presented at the 2022 ASH Annual Meeting indicate a 73.3% overall response rate and 60% complete.

Foresight Diagnostics Announces Three Presentations Highlighting Clinical Studies Using Patented PhasED-Seq® MRD Platform at the 64th American Society of Hematology Annual Meeting and Exposition

PhasED-Seq ctDNA detection enables accurate and predictive treatment response monitoring and clinical prognosis in patients with B-cell lymphoma.A.

Foresight Diagnostics Announces Three Presentations Highlighting Clinical Studies Using Patented PhasED-Seq® MRD Platform at the 64th American Society of Hematology Annual Meeting and Exposition

/PRNewswire/ Foresight Diagnostics, a leader in minimal residual disease (MRD) detection technology, announced today that three studies utilizing their.